ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consider Isa-Kd a New SoC? | VuMedi

UCSF School of Medicine

ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consider Isa-Kd a New SoC?

By UCSF School of Medicine FEATURING Thomas Martin

By UCSF School of Medicine FEATURING Thomas Martin

194 views

January 19, 2021

0 Comments

Login to view comments. Click here to Login